57213-48-6

Basic information

• Product Name: L-3-Cyanophenylalanine
• Synonyms: 3-CYANO-L-PHENYLALANINE;(M-CN)PHE-OH;M-CYANO-L-PHENYLALANINE;L-3-CYANOPHENYLALANINE;L-3-CYANOPHE;H-M-CYANO-L-PHE-OH;H-PHE(3-CN)-OH;H-PHE(M-CN)-OH
• CAS NO: 57213-48-6
• Molecular Formula: C₁₀H₁₀N₂O₂
• Molecular Weight: 190.2
• Product Categories: Amino Acids;Phenylalanine analogs and other aromatic alpha amino acids;a-amino
• Mol File: 57213-48-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 325.7°C (rough estimate)
• Flash Point: 185.127 °C
• Appearance: White to slightly yellow/Powder
• Density: 1.2167 (rough estimate)
• Refractive Index: 1.6300 (estimate)
• Storage Temp.: Store at 0°C
• PKA: 2.14±0.10(Predicted)
• CAS DataBase Reference: L-3-Cyanophenylalanine(CAS DataBase Reference)
• NIST Chemistry Reference: L-3-Cyanophenylalanine(57213-48-6)
• EPA Substance Registry System: L-3-Cyanophenylalanine(57213-48-6)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22
• Safety Statements: 26-37/39-37/38
• RIDADR: UN3439
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 57213-48-6(Hazardous Substances Data)

Usage

Chemical Properties

white to slightly yellow powder

Upstream product

• 28188-41-2 m-(bromomethyl)benzonitrile 
• 367272-51-3 N-acetyl-3-cyano-(D/L)-phenylalanine 
• 169949-48-8 3-cyano-(R,S)-phenylalanine ethyl ester 

Downstream Products

• 205526-36-9 Fmoc-(3-cyano)-L-phenylalanine 
• 13861-02-4 (S)-3-(2-amino-2-carboxyethyl)benzoic acid 
• 1419857-11-6 3-((3,4-dihydroxyphenethyl)carbamoyl)-L-phenylalanine 
• 1348993-91-8 Pht-Phe(3-CN)-OMe 
• 1348993-89-4 Fmoc-β3hPhe(3-Boc-HN-CH2)-OH 
• 1348994-02-4 Fmoc-Phe(3-Boc-HN-CH₂)-CHN₂ 
• 266999-24-0 (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3-(((tert-butoxycarbonyl)amino)methyl)phenyl)propanoic acid 
• 1348993-99-6 H-Phe(3-Boc-HN-CH₂)-OH 
• 1348993-96-3 Pht-Phe(3-Boc-HN-CH₂)-OMe 

Relevant articles and documents

Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1)

The L-type amino acid transporter 1 (LAT1, SLC7A5) transports essential amino acids across the blood-brain barrier (BBB) and into cancer cells. To utilize LAT1 for drug delivery, potent amino acid promoieties are desired, as prodrugs must compete with millimolar concentrations of endogenous amino acids. To better understand ligand-transporter interactions that could improve potency, we developed structural LAT1 models to guide the design of substituted analogues of phenylalanine and histidine. Furthermore, we evaluated the structure-activity relationship (SAR) for both enantiomers of naturally occurring LAT1 substrates. Analogues were tested in cis-inhibition and trans-stimulation cell assays to determine potency and uptake rate. Surprisingly, LAT1 can transport amino acid-like substrates with wide-ranging polarities including those containing ionizable substituents. Additionally, the rate of LAT1 transport was generally nonstereoselective even though enantiomers likely exhibit different binding modes. Our findings have broad implications to the development of new treatments for brain disorders and cancer.

HYDROXYAMIDINE AND HYDROXYGUANIDINE COMPOUNDS AS UROKINASE INHIBITORS

The invention relates to novel compounds for the inhibition of the urokinase plasminogen activator (uPA) with high bioavailability and which can also be administered orally, and to the use thereof as therapeutic active ingredients for the treatment of urokinase or/and urokinase receptor associated diseases, such as, for example, tumours and metastization. The invention especially relates to compounds (I) and (II) that contain hydroxyamidine or hydroxyguanidine groups, wherein E represents a group consisting of (a).